Trevor, a 59-year-old individual, began experiencing cardiovascular symptoms during his 30s, leading to his hospitalization on 24 separate occasions due to these issues. In February 2022, Trevor suffered from persistent angina, prompting his doctor to suggest Reducer therapy. This treatment not only alleviated his symptoms but also enhanced his overall activity level and quality of life.

Testimonial

It is the best thing I’ve ever done. It’s improved my quality of life and I’m getting out and about and starting to move. That’s more than I could have asked for.


Individual patient stories. Results may vary.

*Shockwave Reducer is CE-marked in Europe and has been implanted in over 3,500 patients. It is currently under clinical investigation in the US.

CAUTION: In the United States, the Shockwave Reducer is an investigational device, limited by United States law to investigational use. The Reducer is subject of Investigational testing and is being studied in the COSIRA-II trial in Canada. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability. Prior to use, please reference the Instructions for Use for more information on warnings, precautions and adverse events: ifu.neovasc.com